Multiple thrombotic events following warfarin reversal [2]

Internal Medicine Journal

Volumn 37, Issue 8, 2007, Pages 580-581

  Ratnaweera, M ^a   Janowski, W ^a   Simmons, D ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; VITAMIN K GROUP; WARFARIN;

AGED; ANTICOAGULANT THERAPY; BRAIN INFARCTION; CASE REPORT; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; CEREBRAL INFARCTION; HUMANS; MALE; PROTHROMBIN; PULMONARY EMBOLISM; WARFARIN;

EID: 34447525533     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2007.01423.x     Document Type: Letter

References (6)

1. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aus 2004 114:492 7.
2. Hanley JP. Warfarin reversal. BMJ 2004 57:1132 9.
3. Kohler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999 95:S13 S17.
4. Konig H. Prothrombin overload causes thromboembolic complications. Thromb Haemost 2005 94:1338 9.
5. Sullivan DW, Purdy LJ, Billingham M, Glader BE. Fatal myocardial infarction following therapy with prothrombin complex concentrates. Pediatrics 1984 74:279 81.
6. Van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ et al. Individualised dosing regimen for prothrombin complex concentrates. J Thromb Res 2006 118:313 20.